INTRODUCTION 1
described previously (50). Hemotoxylin and eosin (H and E) stained sections were 1 examined by light microscopy for evidence of injury in a blind manner by an ACVP 2 board certified veterinary pathologist (Kock). The sections were evaluated for overall 3 cellularity/consolidation, alveolar wall thickness, degree of edema fluid present, and 4 infiltrating neutrophils and macrophages in the airways (alveoli and bronchioles) and 5 interstitium. Each parameter was given a subjective score of 0-5, with 0 being 6 considered normal or unaffected and 5 representing the marked change. Averages 7 from each parameter were added together to give the final inflammatory score for each 8 group. 9 10 ELISA. Serum antibody responses to RB50 or LPaV were quantified by coating 96-well 11 flat bottom plates with either strain. Overnight cultures of respective strains were diluted 12 to 0.05 OD 600 /100 l in 0.1M sodium carbonate/sodium bicarbonate buffer and the 13 plates were incubated at 4 0 C overnight. Washing and blocking were carried out as 14 described previously (50). Serum from RB50 or LPaV-infected mice was serially diluted 15 and added to the plates as the primary antibody. The total IgG antibodies were detected 16 using HRP-conjugated goat anti-mouse antibody (1:2000) . Absorbance at 450nm was 17 determined using Labsystems Multiskan Plus plate reader. The OD 450 readings were 18 plotted against the corresponding dilutions and end point titers were determined as 19 previously described (50) . 20
21
Opsonophagocytosis Assays. The opsonophagocytosis assays were carried out 22 using the murine macrophage cell line J774A.1 as described previously (50). Briefly, 23
on October 2, 2017 by guest http://iai.asm.org/ Downloaded from PBS or different dilutions of sera from naïve LPaV-infected mice were heat inactivated 1 at 55 0 C and incubated with 2 x 10 6 CFU of RB50. Subsequently, the bacterial-sera 2 suspensions were added to the macrophage cells at an MOI of 1:10. The plates were 3 incubated at 37 0 C for 1 h. Following gentamycin treatment, the number of bacteria that 4 were phagocytosed was enumerated by lysing the macrophage cells and plating 5 different dilutions. and BipA have little if any effect on the ability of B. bronchiseptica to colonize the nasal 10 cavity (12, 28, 31, 39, 49) . Since Bordetella species express multiple adhesins and 11 toxins, we hypothesized that while the lack of individual factors may not have an effect, 12 the simultaneous absence of these may lead to a defect in nasal colonization. In order 13
to test this hypothesis, we constructed a penta-mutant (LPaV) with in-frame deletions in 14 prn, cyaA, fhaB, fimBCD and bipA. Immuonblotting of the outermembrane fractions of 15 the LPaV strain using convalescent phase sera from RB50-infected mouse confirmed 16 the absence of these proteins (data not shown). Moreover, B. bronchiseptica does not 17 express PT because of inactivating mutations in the ptx promoter (21). Thus, LPaV 18 does not produce any of the protein homologs included in the current Pa vaccines. 19
The colonization kinetics of the mouse respiratory tract by the LPaV strain was 20 compared with that of the wild type strain RB50. Consistent with previous results, RB50 21 was recovered from the nasal septa, tracheas and the lungs of all the animals at high 22 numbers at 1, 3 and 14 days post-inoculation ( Fig. 1) (22) . At 30 days post-infection 23 while RB50 was cleared from the trachea and the lungs, greater than 1000 CFU were 1 recovered from the nasal septum. In contrast, the LPaV mutant displayed a drastic 2 defect in colonization of the trachea and the lungs at all time points examined (Fig. 1) . 3
As early as 1 day post-challenge, significantly lower numbers of bacteria were 4 recovered from the lungs and trachea of the LPaV-infected mice than those obtained 5 from these organs of the wild type infected mice (Fig. 1) . By 14 days post-infection, the 6
LPaV strain was not recovered from the lungs. Three of five mice completely cleared 7 the LPaV infection from the trachea and in two mice the bacterial load was at the lower 8 limit of detection. However, the ability of this mutant strain to colonize the nasal septum 9 at 14 and 30 days post-infection was indistinguishable from the wild type strain (Fig. 1) . 10
These data suggest that concomitant deletion of fhaB, cyaA, fim, prn and bipA does not 11 significantly affect the ability to persist in the upper respiratory tract. 12
13
The LPaV mutant induces less pathology in the infected mouse lung. 14 In order to determine if decreased colonization of the lower respiratory tract by the 15 mutant strain correlated with reduced pulmonary injury, lungs were collected at 1 and 14 16 days post-challenge, sections were fixed, processed for H and E staining and examined 17 microscopically. At 1 day post-infection, lungs of RB50-infected mice showed extensive 18 alveolar wall thickening mostly due to infiltration of neutrophils and received a mean 19 pathology score, 4.0 (Fig. 2) . At 14 days post-infection, the lungs of this group of 20 infected mice showed enhanced infiltration by macrophages but relatively fewer 21 neutrophils with an average score 3.5. In contrast, lungs from mice infected with LPaV 22 exhibited modest changes with average pathology scores of 1.5 and 1.0 at 1 and 14 23 days, respectively (Fig. 2) . The lungs from PBS-inoculated mice received an average 1 score of 1.0 at both 1 and 14 days post-infection with no evidence of significant injury 2 (Fig. 2) . These observations suggest that LPaV elicits reduced injury to the lungs, 3 possibly due to decreased lung colonization. 49), we measured the anti-Bordetella titers in sera of mice infected with this mutant. 10
ELISAs using RB50 cells as the antigen revealed that LPaV-infected mice had 11 significantly lower anti-Bordetella titers than RB50-infected mice at 30 days post-12 inoculation (Fig. 3) . However, the serum antibody responses were similar in both LPaV-13 infected and RB50-infected mice when LPaV cells were used as the antigen ( vaccine-mediated immune responses (20, 25) . Previous studies have demonstrated that 22 passive immunization with sera from RB50-infected convalescent mice leads to the 23 rapid elimination of B. bronchiseptica from the lower respiratory tract (25, 50) . 1 Therefore, we investigated if adoptive transfer of sera from LPaV-infected animals will 2 provide protection from colonization with the wild type strain RB50 in the mouse 3 respiratory tract. Pooled sera collected from LPaV-infected mice or sterile PBS was 4 transferred intraperitoneally followed by challenge with RB50. Seven days post-5 challenge the bacterial burdens in the nose, trachea and the lungs were determined. 6
While mock-treated mice harbored greater than 10 5 CFU in the lungs, 4 of 5 mice 7 treated with the LPaV serum completely cleared RB50 from the lungs (Fig. 4) . Although 8 not as drastic as in the lungs, passive immunization with LPaV sera also resulted in a 9 significant lowering of the bacterial load in the trachea and 2 of 5 mice that received the 10 LPaV serum had no detectable bacteria at this site (Fig. 4) . Adoptive transfer of LPaV 11 antibodies did not have a significant effect on nasal colonization by RB50 (Fig. 4) . Note 12 that previous studies (25) (50) demonstrate that adoptively transferred anti-Bordetella 13 antibodies have no effect on upper respiratory tract colonization by Bordetella in mice. 14 These results suggest that in spite of lower titers, antibodies elicited during infection of 15 mice with the LPaV strain are efficient in providing protection in the lower respiratory 16 tract against wild type B. bronchiseptica infection. 17
18

Opsonization with anti-LPaV serum enhances phagocytosis of B. bronchiseptica. 19
Antibody mediated bacterial uptake by phagocytes is often correlated with protective 20 efficacy of passively transferred immune sera (43, 50). We examined the efficiency of 21
LPaV serum to promote phagocytosis of RB50 by the murine macrophage cell line 22 J774. PBS and sera collected from naïve mice were utilized as negative controls. There 23 was a dose-dependent increase in the uptake of RB50 by J774 cells when opsonized 1 with the LPaV serum as compared to opsonization with either the serum from naïve 2 mice or PBS only (Fig. 5) . These results suggest that one of the mechanisms for the 3 observed passive protection mediated by anti-LPaV serum is increased opsonization of 4
B. bronchiseptica for phagocytosis. 5 6
Immunization with the LPaV strain elicits cross-protective immunity against both 7 B. bronchiseptica and B. pertussis. 8
Next we investigated the utility of LPaV as a potential live vaccine for B. bronchiseptica. 9
Thirty days post-inoculation with LPaV, mice were challenged with RB50. Bacterial 10 burdens in the lungs, trachea and nasal septum were then determined 7 days post-11 challenge with RB50. Although LPaV is cleared from the trachea and lungs at 30 days 12 post-inoculation, it is still present in nose at this time-point (Fig. 1) . Thus, we utilized 13 hemolysis as a means to distinguish between the colonies of RB50 and LPaV. RB50 14 produces colonies with a distinct hemolytic zone whereas LPaV results in non-hemolytic 15 colonies because of the deletion of the cyaA gene. Compared to the mock-treated mice, 16
LPaV-vaccinated mice completely cleared RB50 infection from the lungs and trachea 17 and bacteria were not recovered from these organs (Fig. 6A) . Similarly, close to a 3 log 18 reduction in the numbers of RB50 colonies was observed from the nose of LPaV-19 vaccinated mice, compared to that from the nose of mock-treated mice (Fig. 6A) . For 20 two of the five vaccinated mice the level of colonization was near the threshold of 21 detection (Fig. 6A) . Although there was no significant differences in the growth of RB50 22 and the LPaV strain in broth cultures (data not shown) and the LPaV strain colonizes 23 on October 2, 2017 by guest http://iai.asm.org/ Downloaded from the nose as efficiently as RB50 (Fig. 1) , we cannot exclude the possibility that the 1 observed reduction in the numbers of RB50 was because of competition with the 2 resident LPaV bacteria in the nasal cavity at the time of challenge. 3
Based on the protection observed with RB50, we determined whether LPaV 4 would generate cross protection against the human pathogen B. pertussis. Despite the 5 caveat of a B. bronchiseptica strain being utilized to examine protection against B. 6 pertussis, the B. bronchispetica-mouse model represents a natural-host animal model 7
and is also analogous and representative of human-B. pertussis infections (22). To 8 precisely count the number of B. pertussis obtained from the nose, bacteria harvested 9 from this site were plated on BG plates containing nalidixic acid and streptomycin. LPaV 10 is susceptible to nalidixic acid. At 3 days post-challenge, the greatest decline in the 11 bacterial load was observed in the trachea, while there was a small but significant 12 decline in the lungs (Fig. 6B) . While the colonization of the nose by B. pertussis at this 13 time point was highly variable, for two of the LPaV-vaccinated mice, the CFU obtained 14 were at or close to the lower limit of detection. At 7 days post-challenge, all the 15 immunized mice had cleared B. pertussis from the trachea. Although at 7 days we did 16 not recover bacteria from the lungs of one of the control mice, when compared to the 17 rest of the mice in this group, the LPaV-immunized mice harbored an average of 50-fold 18 fewer bacteria in the lungs (Fig. 6B ). Compared to three days post-inoculation, the 19 burden of B. pertussis in the nose of the LPaV-vaccinated mice was further lowered at 7 20 days post-inoculation and two of the mice had no detectable bacteria at this site ( We also examined the lungs of LPaV-vaccinated mice following challenge with RB50 or 3
Bp536 to determine whether prior inoculation with this strain would reduce pulmonary 4 injury as a result of infection with wild type B. bronchiseptica or B. pertussis. While the 5 lungs of control mice infected with RB50 had alveolar wall thickening mostly due to the 6 infiltration of mononuclear phagocytes and had an average pathology score of 4.3, the 7 lungs of LPaV-immunized mice demonstrated less injury with a mean score of 1.5 (Fig.  8   7A) . Similarly vaccinated mice that were challenged with Bp536 displayed reduced lung 9 injury with a mean score of 1.6 while the lungs of control mice infected with Bp536 were 10 edematous with an average score of 3.0 (Fig. 7B) . These results show that 11 immunization with LPaV strain lowers lung pathology associated with B. bronchiseptica 12 and B. pertussis infection (Fig. 7) . for the known surface proteins and toxins in nasal colonization (12, 28, 31, 39, 49) . We 9 hypothesized that efficient nasopharyngeal colonization by Bordetellae involves the 10 coordinated participation of multiple virulence factors. We constructed the mutant strain 11
LPaV with the expectation that concurrent deletion of genes encoding for five of the 12 well-studied surface proteins and toxins would drastically reduce colonization of the 13 upper respiratory tract. However to our surprise, this mutant strain was as effective as 14 the wild type strain in colonizing the mouse nasal cavity (Fig. 1) . In contrast, it was 15 essentially cleared from the trachea and the lungs and resulted in reduced pulmonary 16 injury (Figs. 1 & 2) . 17
Encouraged by the observed attenuation in the trachea and the lungs and the 18 resultant minimal damage to the host following infection with LPaV strain, we 19 determined the effectiveness of this mutant as a live vaccine for B. bronchiseptica. We 20 found that prior infection of mice with this mutant conferred protection against a wild 21 type strain of B. bronchiseptica (Fig. 6A) . Immunized animals had a significant albeit 22 weaker humoral immune response compared to animals infected with the wild type 23 on October 2, 2017 by guest http://iai.asm.org/ Downloaded from strain (Fig. 3) . Adoptive transfer of sera from immunized animals rapidly eliminated B. 1 bronchiseptica from the lungs and reduced bacterial burdens from the trachea, 2 suggesting that protection mediated by this strain in the lower respiratory tract is 3 mediated in part by antibodies (Fig. 4) . A potential utility of this mutant strain is as a live 4 attenuated vaccine against B. bronchiseptica in animals. The currently available 5 vaccines against B. bronchiseptica are live, attenuated or heat killed bacteria (2, 28, 32, 6 46, 48). One of the problems associated with these is that the genetic mutations that 7 result in the attenuation are not known. Under survival pressures in the host including 8 co-infections with other pathogens, there exists the possibility that such vaccine strains 9 might revert to a virulent form (47, 48). Since the LPaV mutant strain carries genetically 10 defined mutations, it may serve as a safer vaccine. However, because of its ability to 11 persist in the nose of the experimentally infected animals the potential for herd-herd 12 transmission of such a vaccine strain exists. 13
The animal pathogen B. bronchiseptica is considered to be the evolutionary 14 progenitor of the human pathogen B. pertussis (41). Despite this evolutionary 15 relationship, there are distinct differences in genome sizes and gene expression 16 patterns between these two species. B. pertussis has a smaller genome and contains a 17 large number of pseudogenes, many of which have been inactivated by insertion 18 elements, in-frame stop codons, and frameshift mutations (13). Our finding that 19 immunization with LPaV provided cross-species protection against B. pertussis (Fig. 6B 
